Earnings summary
4D Molecular Therapeutics, Inc. Q3 2025 results
Snapshot
4D Molecular Therapeutics, Inc. reported $0M of revenue in Q3 2025, up 2900.0% year over year, with diluted EPS of $-1.01 and an operating margin of -67983.3%.
- Revenue
- $0M
- YoY growth
- +2900.0%
- Diluted EPS
- $-1.01
- Operating margin
- -67983.3%
$0M
Revenue
+2900.0%
YoY growth
$-1.01
Diluted EPS
-67983.3%
Operating margin